VaxGen plans to relist shares

South San Francisco biopharmaceutical firm VaxGen Inc. (Pink sheets: VXGN) said it is now current on its financial reporting obligations with the U.S. Security and Exchange Commission and plans to relist its common stock on a nationally recognized stock exchange.

VaxGen has suffered a series of setbacks.

The company, which suffered a well publicized failure of an AIDS vaccine it was developing in 2003, was delisted from the Nasdaq exchange in 2004 for failing to promptly file financial reports with federal authorities as required. It then lost a U.S. government contract to provide an anthrax vaccine in December 2006 after missing a key deadline.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

New plan provides a road map to better transit for Bayview residents

SFMTA to review suite of 101 projects designed to improve community safety and access

Mandelman bringing bathhouses back to The City

New ordinance would amend health code restrictions imposed in 1980s

Bernie Sanders draws large crowd at Richmond rally

Democratic presidential candidate U.S. Sen. Bernie Sanders drew a large crowd at… Continue reading

Quarantined ship passengers sequestered at Travis Air Force Base

More than a dozen have tested positive for coronavirus

Japanese American family at heart of beloved Golden Gate Park garden

The Japanese Tea Garden, the oldest public Japanese garden in North America,… Continue reading

Most Read